Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

A review examines how intron retention may influence ALS biology

Original source

Intron retention in health and amyotrophic lateral sclerosis.Brain · 3 August 2026 (opens in a new tab)

Compass summarised this from the study's abstract.

Study details

Study type
Review
Studied in
Human, Animal

A review describes intron retention, in which sections of RNA called introns remain in messenger RNA, as a potentially important process in amyotrophic lateral sclerosis (ALS). It discusses possible effects on RNA-binding proteins, cellular structures and gene regulation, and considers intron retention as a possible future therapeutic target.

Why this matters

The review may help researchers identify mechanisms to study in ALS and potential targets for future treatment research. It does not establish a treatment or show a benefit for people living with ALS.

Limitations and context

This is a review article, not a clinical trial or a new treatment study. It discusses emerging and potential roles for intron retention, so its therapeutic relevance still needs to be tested in disease models and people with ALS.

Summarised by Compass 8 August 2026

This summary was generated by AI from the source listed above. It is not medical advice, so read the original source for anything that affects your care.

Bibliographic data from PubMed is courtesy of the U.S. National Library of Medicine. Compass does not reproduce source abstracts and may not reflect the most current record.

Relevant to you?